INTERIM REPORT JANUARY–SEPTEMBER 2011
The January–September period and the third quarter 2011 in brief · Net sales amounted to MSEK 0.0 (0.0) · Net loss was MSEK 176.0 (113.4), whereof the third quarter MSEK 51.1 (34.4) · Loss per share was SEK 0.45 (0.48), whereof the third quarter SEK 0.13 (0.14) · Cash flow from operating activities was MSEK -160.4 (-114.6), whereof the third quarter MSEK -47.7 (-33.7).The difference from the previous period concerns costs related to the phase III program for eprotirome · Cash and cash equivalents and other short-term investments totalled MSEK 198.4 (116.2) at the end of the